Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice

Emi Tanaka1,2, Yuko Ogawa1, Takeo Mukai3, Yoshiaki Sato4, Takashi Hamazaki2, Tokiko Nagamura-Inoue6, Mariko Harada-Shiba1, Haruo Shintaku2 and Masahiro Tsuji1*

1Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, Japan, 2Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Department of Cell Processing and Transfusion, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 4Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, Japan

Neonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of intravenously administered human umbilical cord-derived MSCs (UC-MSCs) in neonatal stroke mice. Pups underwent permanent middle cerebral artery occlusion at postnatal day 12 (P12), and low-dose (1 × 10^4) or high-dose (1 × 10^5) UC-MSCs were administered intravenously 48 h after the insult (P14). To evaluate the effect of the UC-MSC treatment, neurological behavior and cerebral blood flow were measured, and neuroanatomical analysis was performed at P28. To investigate the mechanisms of intravenously injected UC-MSCs, systemic blood flowmetry, in vivo imaging and human brain-derived neurotrophic factor (BDNF) measurements were performed. Functional disability was significantly improved in the high-dose UC-MSC group when compared with the vehicle group, but cerebral blood flow and cerebral hemispheric volume were not restored by UC-MSC therapy. The level of exogenous human BDNF was elevated only in the cerebrospinal fluid of one pup 24 h after UC-MSC injection, and in vivo imaging revealed that most UC-MSCs were trapped in the lungs and disappeared in a week without migration toward the brain or other organs. We found that systemic blood flow was stable over the 10 min after cell administration and that there were no differences in mortality among the groups. Immunohistopathological assessment showed that the percent area of Iba1-positive staining in the peri-infarct cortex was significantly reduced with the high-dose UC-MSC treatment compared with the vehicle treatment. These results suggest that intravenous administration of UC-MSCs is safe for a mouse model of neonatal stroke and improves dysfunction after middle cerebral artery occlusion by modulating the microglial reaction in the peri-infarct cortex.

Keywords: mesenchymal stem cell, umbilical cord-derived mesenchymal stem cell, neonatal stroke, neonatal brain injury, intravenous administration
INTRODUCTION

Neonatal stroke is a common cause of acute neonatal encephalopathy and frequently results in neurological impairments such as cerebral palsy, cognitive disorders, and seizures (1, 2). The incidence of neonatal arterial ischemic stroke is 1 per 3,500 to 7,700 neonates, and the frequency of neonatal arterial ischemic stroke diagnosis has increased due to the advancement of imaging techniques (3, 4). Although neonates with stroke may present features of hypoxic-ischemic encephalopathy (HIE) (5, 6), therapeutic hypothermia has not currently been proven effective for neonatal stroke despite its efficacy in HIE. In addition, most neonatal stroke patients are recognized only retrospectively with emerging seizures or hemiparesis days after birth, hence the patients are likely to miss the opportunity of receiving acute neuroprotective treatments. There is currently no effective treatment for neonatal stroke. A novel therapeutic strategy to improve the outcome of neonatal stroke is needed.

Recently, many researchers have focused on cell therapies as novel treatments for neonatal brain injury. Our group has focused on the use of umbilical cord blood (UCB) for its advantage in feasibility to clinical applications (7), and previously we have shown the benefit of systemic administration of human UCB cells in animal models of neonatal encephalopathy (8, 9). Subsequently, we are conducting a clinical trial of autologous UCB transplantation for neonates with HIE (National Institutes of Health, ClinicalTrials.gov: NCT02256618). However, more than half of neonatal stroke patients do not present signs or symptoms at birth, hence physicians and parents may not recognize the need for preserving their own UCB. Even if the need is recognized, it is not always possible to collect their own UCB, especially when babies are unexpectedly born with severe asphyxia. An alternative cell source for neonatal brain injury is needed, and mesenchymal stem cells (MSCs) have emerged as a promising candidate. MSCs are isolated from umbilical cord, UCB, and placenta, as well as from bone marrow and adipose tissue, and they can be easily expanded in culture (10). Regardless of the cell source, each MSC population has a self-renewal capacity, a multi-lineage differentiation ability, and the potential for migration toward an inflamed or injured site (11, 12).

Umbilical cord-derived MSCs (UC-MSCs) have been proposed as a preferable cell source for regenerative medicine and immunotherapy, as they possess faster self-renewal, higher multipotency, and less immunogenicity than the features of born marrow-derived MSCs (13–16) and adipose-derived MSCs (17, 18). Considering these advantages and the demand for a cell source for neonates who do not have their own UCB, we are preparing to produce clinical grade off-the-shelf UC-MSCs for the next clinical application and for broad spectrum use in neonates with brain injuries. We have shown that intravenous administration of UC-MSCs ameliorates injuries via attenuating reactive gliosis and hypomyelination in a neonatal mouse model of intraventricular hemorrhage (IVH) (19). However, there is no study on UC-MSC in a neonatal stroke model. Regarding the injection route, most studies in models of neonatal brain injury have used local administration of MSCs, such as intraventricular and intranasal injection (20–23). There is a limited number of studies on intravenous MSC treatment for neonatal brain injury, one in sheep model (24) and four in rat models (25–28), and there is no study in mouse model except for our IVH report (19). With respect to studies on UC-MSCs for treatment of neonatal brain injury, most of them examined the effects of a focal injection (29–31). In clinical settings, intravenous administration is more desirable for unstable, sick neonates because it does not require an additional invasive procedure. Our previous study showed that cell distributions vary with injection routes, and more cells were trapped in the lungs when injected intravenously (32). Therefore, it is necessary to demonstrate the safety and efficacy of intravenous administration of UC-MSCs in neonatal animal models. In addition, studies of dosing regimens were limited mainly to UCB cells (33–36), evidence on intravenous MSC dosing is lacking. The main objective of this study was to investigate whether intravenous administration of UC-MSCs is safe and whether this treatment can attenuate brain damage and to determine the optimal dose for ameliorating the neurodevelopmental deficits after neonatal stroke.

MATERIALS AND METHODS

Cell Preparation

Human umbilical cord tissues were obtained from women who underwent cesarean sections after informed consent was obtained. UC-MSCs were isolated as described by Mori et al. (37). Briefly, UC-MSCs were isolated by an improved explant methodology, and fragments were cultured with DMEM medium (kindly provided by RHTO Pharmaceutical Co., Ltd., Osaka, Japan), which is a serum-free culture medium, at 37°C with 5% CO2. After confluence, adherent cells were trypsinized and replated (passage 1). The cells of fourth passage were cryopreserved in a cryoprotectant, STEM-CELLBANKER (ZENOAQ Resource Co., Ltd., Fukushima, Japan) which contains 10% dimethyl sulfoxide (DMSO). The expanded UC-MSCs were validated for their differentiation potential and cell surface molecules as previously described (38). Cells were rapidly thawed in a 37°C water bath just before use without washing. Of note, this cryoprotectant with DMSO has been proven safe for clinical use. When mostly thawed into liquid, the cells in a tube were kept on ice and used within 1–2 h. The viability of UC-MSCs was 91.75 ± 8.30%. The cryoprotectant was used as vehicle in the control group.

Neonatal Stroke Model

All animal research studies were approved by the Experimental Animal Care and Use Committee of the National Cerebral and Cardiovascular Center and was done according to the NIH Guide for the Care and Use of Laboratory Animals.

CB17 male and female mouse pups were used in the experiments (n = 90). Postnatal day 12 (P12) pups, which are thought to be equivalent to full-term human newborns at P0 (39, 40), were divided into a no-surgery control group (n = 6), a sham-surgery group (n = 12), and middle cerebral artery occlusion (MCAO) groups (n = 72). The pups were subjected to permanent MCAO as described previously (41). Under isoflurane anesthesia (4.0% for induction and 1.5–2.0% for maintenance), a hole was made...
in the left temporal bone. The left middle cerebral artery (MCA) was electrocauterized and disconnected just distal to its crossing of the olfactory tract. Pups in the sham group underwent open-skull surgery without MCA electrocoagulation. After the insult, mice were observed for any bleeding and was awakened in the 32°C infant-warmer and then returned to their dams. All mice tolerated the MCAO procedure, and there was no surgical mortality. The numbers of mouse pups used in each cohort are summarized in Table 1. The blood flow measurement, a battery of behavioral tests, and morphological evaluations were done in cohort A. A flow cytometry beads assay and in vivo imaging were done in cohorts B and C, respectively. All the other experiments were performed in cohort A (Figure 1).

**Table 1** Numbers of mice used in the experiments.

| Cohort | Control | Sham | Vehicle | Low-dose $1 \times 10^4$ | High-dose $1 \times 10^5$ |
|--------|---------|------|---------|-------------------------|--------------------------|
| A      | 12      | 13   | 13      | 16                      |                          |
| B      | 6       | 9    |         | 13                      |                          |
| C      | 1       |      | 7       |                          |                          |

Mice in cohort A were used for the blood flow measurement, behavioral, and histological evaluations; cohort B for blood and cerebrospinal fluid (CSF) sampling; and cohort C for in vivo imaging of injected cells.

**Cell Administration**

At 48 h after the MCAO procedure (at P14), mice were randomly divided into three groups: vehicle ($n = 23$), low-dose UC-MSCs ($1 \times 10^4$ cells, $n = 13$), and high-dose UC-MSCs ($1 \times 10^5$ cells, $n = 36$). From our previous study with a cell therapy (8) and from a clinical standpoint, we thought that 48 h after the MCAO would be the optimal timing of cell administration for neonatal stroke; neonatal stroke is rarely diagnosed on the first day of life, rather diagnosed a few days after the birth in many cases. Pups in the UC-MSC groups were administered frozen-thawed UC-MSCs in 60 µl of STEM-CELLBANKER cryoprotectant. Pups in the vehicle group were administered cryoprotectant alone. After incising the skin in the left inguinal region, UC-MSCs were infused or vehicle was infused into the femoral vein using a 35-G needle under isoflurane anesthesia, slowly administered over 1 min as described previously (32). Under the microscope, we were able to directly observe the injection flow through the transparent vein when the needle insertion was optimal.

**Systemic and Cerebral Blood Flowmetry**

Blood flow of the body surface and cerebral surface were measured by a laser speckle flowmetry imaging system (OmegazoneOZ-1, Omegawave Inc., Tokyo, Japan). Flowmetry of the body surface as a representative of systemic blood flow was performed before...
and immediately after injection. First, under isoflurane anesthesia, pre-flow images were acquired every 5 s, and vehicle was administered or UC-MSCs were administered over 1 min followed by 30 s hemostasis with a swab. Second, post-flow images were sequentially taken every 5 s for 10 min. We set the region of interest in the chest, and the average blood flow per minute was compared with that from the pre-flow measurements (vehicle $n = 7$, low-dose $n = 8$, and high-dose $n = 8$).

Cerebral blood flow (CBF) was measured 24 h after injection (at P15) as described previously (42). We evaluated the three ROIs such as ischemic core, penumbra and MCA region (Figure 2C). Data were presented as CBF ratio, ipsilateral/contralateral hemisphere (sham $n = 10$, vehicle $n = 10$, low-dose $n = 10$, high-dose $n = 12$).

**Behavioral Tests**
To evaluate the effects on motor and sensory functions, the following four behavioral tests were performed: a cylinder test, a dynamic plantar test, a rotarod test, and an open-field test.

The cylinder test was performed on P15. Asymmetry of forelimb use was assessed during rearing in a transparent acrylic cylinder (43). We videotaped 20 rearing movements, counted wall touches by each forelimb separately, and analyzed forepaw use preference as follows: (nonimpaired side [left] − impaired side [right])/(nonimpaired + impaired sides) × 100 (sham $n = 12$, vehicle $n = 18$, low-dose $n = 13$, and high-dose $n = 14$).

The dynamic plantar test was performed on P16. We measured responses to von Frey filaments to assess sensory function as described previously (44, 45). Mice were acclimated in an elevated mesh floored cage and tested using the Dynamic Plantar Aesthesiometer (Ugo Basile, Varese, Italy). A filament was pushed up mechanically from beneath each paw, which increased in force gradually from 0 to 40 g over the course of 50 s until the mouse withdrew its paw. Each mouse received three trials per paw, the withdrawal time was noted, and the average was calculated as follows: (nonimpaired side − impaired side)
order to distinguish from non-specific background staining. The GFAP-positive astrocytes and Iba1-positive microglia were segmented by applying an appropriate threshold in gray value in the processed brains. The GFAP-positive astrocytes and Iba1-positive microglia were localized using a slide fluorescent microscope and analyzed with Leica Application Suite X (Leica Microsystems, Wetzlar, Germany). The number of GFAP-positive astrocytes and Iba1-positive microglia in the cortical areas was counted and compared.

For the open-field test, locomotor and exploratory behaviors were evaluated at 8–10 days after the insult (P20–P22) as described previously (8). Animals were allowed to act freely in a box (30 cm x 30 cm) for 30 min in the light and for 30 min in the dark. The number of beam crossings by an animal was counted and scored as locomotion for the horizontal movement and as rearing for the vertical movement.

Tissue Preparation and Morphology

A morphological evaluation of the brain was performed as previously described (46, 47). On P28, mice were sacrificed with pentobarbital i.p. and transcardially perfused with phosphate-buffered saline and then with 4% paraformaldehyde. Subsequently, the whole brain was removed and immersed overnight in the same fixative. Fixed brains were cut coronally into 1-mm slices and the hemispheric areas were measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The hemispheric volume was estimated by integration of the hemispheric areas. The cerebral hemispheric volume ratio was calculated as follows: viable ipsilateral hemispheric volume/contralateral hemispheric volume.

Immunohistochemistry

The processed brains were embedded in paraffin, and 5-μm coronal sections were prepared for every 1 mm. For immunohistochemical detection, anti-mouse GFAP (glial fibrillary acidic protein, a marker of astrocytes) antibody (1:100; Merck Millipore, Burlington, VT, USA), and anti-rabbit Iba1 (ionized calcium binding adaptor molecule, a marker of microglia 1) antibody (1:200; WAKO, Osaka, Japan,) were used. The second-antibody was a goat-anti-mouse IgG polyclonal antibody (Nichirei Bioscience Inc., Tokyo, Japan). Slices were stained with 3,3′-diaminobenzidine (DAB) with hydrogen peroxide. The GFAP-positive astrocytes and Iba1-positive microglia were segmented by applying an appropriate threshold in gray value in order to distinguish from non-specific background staining. The percent areas (segmented area/total 400 μm x 400 μm area) were calculated using ImageJ software. The regions of interest (ROIs), i.e., square frame, were laid not to include tissue absent area or necrotic area by an examiner who was blinded to the experimental group of the mice. Four regions were determined from a section containing both the hippocampus and striatum; the peri-infarct cortex, hippocampus, subcortical white matter, and non-infarct cortex in an area of 400 μm x 400 μm. We calculated the percent area for two ROIs in one slice per region per animal (n = 5 per group).

Flow Cytometry Beads Assay

In cohort B (Figure 1), the no-surgery control and MCAO mice were prepared. The MCAO mice were subjected to intravenous administration of vehicle or UC-MSCs (1 × 10^5 cells; control n = 6, vehicle n = 6, and UC-MSCs n = 13). Mouse serum and cerebrospinal fluid (CSF) were collected 24 h after injection, and the concentration of human brain-derived neurotrophic factor (BDNF) secreted from human UC-MSCs was measured using a bead immunoassay as previously described (19). CSF was collected by puncture of cisterna magna with a 25-G needle and a capillary glass under microscope. Subsequently, blood was collected by cardiac puncture using a 1 ml syringe and a 26-G needle, and centrifuged to collect the serum. We quantified human BDNF with the HQ-Plex kit (Bay Bioscience Co., Ltd., Kobe, Japan). All samples were analyzed in triplicate according to the manufacturer’s instructions. Bead fluorescence readings were done by a BD™ FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA).

In Vivo Imaging of UC-MSCs

In cohort C (Figure 1), eight MCAO mice received intravenous administration of vehicle (n = 1) or 1 × 10^5 UC-MSCs (n = 7) 48 h after insult. UC-MSCs were traced using an IVIS Lumina II imaging system (Xenogen Corporation, Alameda, CA, USA) at 2 h, 24 h, 48 h, 4 days, and 7 days after the intravenous injection. Mice were given an intraperitoneal injection of d-luciferin (WAKO, Osaka, Japan) at a dose of 150 mg/kg 10 min before each imaging time point. Images were captured with an exposure time of 1 min under isoflurane anesthesia in a chamber, and images were analyzed using Living Image 3.0 software (Caliper Life Sciences, Waltham, MA, USA).

Statistical Analysis

The mortality rate of the animals was analyzed using the Fisher’s exact test. Calculated values such as CBF ratios, the cylinder and planter test results, cerebral hemispheric volumes, and percent areas of immunohistological staining were assessed using a Kruskal–Wallis test followed by Dunn’s test. Absolute values or temporal sequences that include systemic blood flow and the rotarod and open-field test results were assessed using two-way repeated measures ANOVA. The significance level was established at p < 0.05. The results are presented as the mean ± SEM in bar graphs or box plots (maximum, quartile point, medium, and minimum). All data were analyzed using JMP 12.2.0 software (SAS Institute, Cary, NC, USA).

RESULTS

Mortality

In this study, 62 mice survived for two weeks after the insult, and seven died (Table 2). One mouse in the high-dose UC-MSC group died approximately 10 min after induction of anesthesia and a few minutes after cell administration. The rest died during a remote period approximately 7 days after the insult, indicating that the deaths may not be due directly to cell administration but rather due to weakness from the MCAO injury.
Additionally, we evaluated spontaneous activity in an open-field test during P20–22. There were no differences among the groups (Figures 3D,E).

**Morphology**

Cerebral hemispheric volume was estimated in fixed brain tissue. The volumes were consistent across all animals in the sham group (Figures 4A,B). MCAO caused a significant volume loss in the vehicle group. There was no improvement in the volume by UC-MSC administration compared with the volume in the vehicle group.

**Immunohistopathology**

We observed inflammation in sections of the injured brains at P28. MCAO significantly increased the percent areas of GFAP- and Iba1-positive cells in the peri-infarct cortex and subcortical white matter in the vehicle group compared with those in the sham group. There was no significant increase in the areas of the hippocampus or non-infarct cortex of the vehicle group. In the peri-infarct cortex, high-dose UC-MSCs significantly reduced the Iba1-positive percent area, and low-dose UC-MSCs also showed the same trend toward reduction ($p = 0.083$). Therefore, this result shows that high-dose UC-MSCs decreased the microglial accumulation in the peri-infarct cortex (Figure 5).

**Detection of Human BDNF In Vivo**

We assessed the presence of the neurotrophic factor BDNF from human UC-MSCs. Both serum and CSF were assessed 24 h after injection (P15). There was no detection of BDNF in the control group (Figure 6). Only one of the 13 mice treated with UC-MSCs showed an elevated level of human BDNF in CSF. A few mice had minimal equivocal levels of BDNF, which were inconclusive as to whether the observed increases were meaningful.

**In Vivo Imaging**

An in vivo imaging system was used to quantify the photon flux in the vehicle- and UC-MSC-treated groups at 3 h, 24 h, 48 h, 4 days, and 7 days after injection. The images revealed that intravenously injected UC-MSCs were rapidly trapped in the lungs. The intensity of photon flux was highest in the first image acquisition of the UC-MSC mice and then decreased over time, disappearing by 7 days. We did not detect the signals in other organs such as the brain or spleen (Figure 7).

**DISCUSSION**

In this study, we demonstrated that intravenous administration of human UC-MSCs following MCAO in neonatal mice was safe and attenuated damages in neurodevelopmental behaviors and glial cell reaction after neonatal stroke. We found that systemic blood flow was stable during 10 min after cell administration despite most UC-MSCs being trapped in the lungs and that there were no differences in mortality among the groups. Although the CBF and cerebral hemispheric volume were not restored after UC-MSC administration, neurological performance was significantly improved.

### TABLE 2 | Mortality rate.

| Group       | Time after injection | Sham | Vehicle | Low dose $1 \times 10^4$ | High dose $1 \times 10^5$ |
|-------------|----------------------|------|---------|-------------------------|--------------------------|
| Dead/total | 24 h                 | 0/12 | 0/23    | 0/13                    | 1/36                     |
|            | 2 weeks              | 1/12 | 1/14    | 1/13                    | 4/23                     |

Mortality rates at 24 h (postnatal day 15, P15) and 2 weeks (P28) after the vehicle or umbilical cord-derived mesenchymal stem cell (UC-MSC) injection were not different between the groups.
Behavioral tests: the cylinder test, dynamic plantar test, rotarod test, and open-field test. (A) In the cylinder test performed at P15, significant asymmetrical forepaw use was observed in the vehicle group. After administration of high-dose umbilical cord-derived MSCs, forepaw preference significantly improved. Wall touches by the left of right forepaw were measured separately, and paw preference with wall touches was calculated as \((\text{nonimpaired side} - \text{impaired side}) / (\text{nonimpaired side} + \text{impaired side}) \times 100\). * \(p < 0.05\) (sham \(n = 12\), vehicle \(n = 18\), low-dose \(n = 13\), and high-dose \(n = 14\)). (B) The dynamic plantar test was performed at P15 to assess the extent of sensory deficit. The forepaw of vehicle mice showed significant asymmetrical dullness compared with that of the sham mice. The high-dose UC-MSC mice showed a trend toward improvement. Average withdrawal time was calculated as \((\text{nonimpaired} - \text{impaired}) / (\text{nonimpaired} + \text{impaired}) \times 100\). * \(p < 0.05\) and # \(p = 0.092\) (sham \(n = 12\), vehicle \(n = 13\), low-dose \(n = 15\), and high-dose \(n = 15\)). (C) In the rotarod test at P16 and P23, there were no significant differences among the groups (P16: sham \(n = 12\), vehicle \(n = 13\), low-dose \(n = 13\), and high-dose \(n = 15\); and P23: sham \(n = 10\), vehicle \(n = 12\), low-dose \(n = 13\), and high-dose \(n = 11\)). (D,E) The open-field test was performed from P20 to P22. There were no significant intergroup differences with respect to either locomotion, i.e., spontaneous horizontal movement, or rearing, i.e., spontaneous vertical movement (\(n = 11–13\) in each group).

This is the first report from the following two standpoints: (1) UC-MSCs were used in a neonatal stroke model, and (2) two cell doses were compared in a scheme of intravenous MSC injection for neonatal brain injury. To our knowledge, there is no study on the use of UC-MSCs for neonatal stroke. There are a few studies in the literature that examined the effects of UC-MSCs for neonatal brain injury and showed functional recovery (19, 27–30). As there is no proven effective therapy for neonatal stroke, we investigated whether UC-MSCs improve neurological outcomes of neonatal stroke.

No report has demonstrated an optimal dose of intravenous MSCs injection in a neonatal brain injury model. Our current study aimed to determine an optimal MSCs dose for neonatal brain injuries that can be translated into clinical settings. To this end, two different doses of UC-MSC were compared for their effectiveness and safety in the behavioral tests and histological assessments. The higher dose was chosen based on the results of our previous study where intravenous administration of \(1 \times 10^5\) human UCB CD34+ cells was found beneficial in the same mouse model of neonatal stroke (8). The lower dose of \(1 \times 10^4\) cells was chosen to see whether these beneficial effects could be obtained even after lowering dosage. In light of clinical translation, lower dose is considered preferable because of limited availability of these cells and cost. Although there were no differences in the CBF or morphology, mice treated with the high-dose of UC-MSCs (\(1 \times 10^5\) cells) showed a significant improvement in neurological function and glial responses after MCAO, and mice treated with the low-dose of UC-MSCs (\(1 \times 10^4\) cells) showed a trend toward improvement. Studies of MSC dosing are limited only to focal injection (48–50); Donega et al. showed that
evaluation in our previous study, in vivo imaging in the present study demonstrated that intravenously injected US-MSCs were mainly trapped in the lungs (32). We were concerned about the possibility of a pulmonary embolism caused by the administered cells, so we measured systemic blood flow before and after the intravenous injection to rule out that possibility. Although a study of large animals demonstrated that the oxygen saturation after intravenous transplantation of MSCs was not significantly changed (52), there is no such study in neonatal mouse model. The stability in systemic blood flow suggests that the intravenous injection of UC-MSCs does not cause significant blood vessel embolism and is safe for newborn humans as well.

We studied how intravenously injected UC-MSCs distribute and act in the injured brain. Contrary to expectations, only one of the 13 mice treated with human UC-MSCs exhibited an increase in human BDNF in serum and CSF, and in vivo imaging showed that no animal exhibited migration of UC-MSCs toward the brain. We previously showed that intravenous administration of human UC-MSCs increased the levels of human BDNF and nerve growth factor in serum and CSF in about half of the mouse pups that were subjected to IVH at P5 (19). The previous results demonstrated the time-dependent migration of UC-MSCs toward the brain at 3 days after the injection, whereas this study did not detect the cell migration toward the brain. This contradiction may be due to differences in the pathophysiology (hemorrhage-induced vs. ischemia-induced injury) and the ages of animals used. Extracellular hemoglobin and their metabolites from IVH cause inflammation and contribute to mRNA up-regulation of pro-inflammatory cytokines after 72 h (53). These cytokines increase blood-brain barrier (BBB) permeability, leading to a consequent increase in endothelial adhesion molecules and modifications of the molecular composition/functional state of tight junctions. In contrast, a report showed that MCAO-induced BBB dysfunction was rather moderate and stable than that by LPS- or cold-induced injury (54); although, the report did not directly compare the IVH and MCAO methods. We measured human BDNF excreted from exogenous UC-MSCs but not endogenous murine BDNF. Ahn et al. showed a protective effect of human UCB-derived MSCs and an increase in endogenous BDNF expression 2 and 5 days after an intraventricular injection to IVH model rats (55). Taken together, the variety of inflammatory responses among different models critically influences the fate and actions of MSCs, and therapeutic effect may be induced mainly by the endogenous response in the recipient and not by direct action of the donor cells.

As there was no evidence of migration toward the injured brain tissue or restoration in CBF, we do not consider that cell replacement and improved cerebral perfusion contributed to the neurological improvement in this study. Similar to our current results, studies in the literature often show behavioral improvement without neuroanatomical improvement. One of the mechanisms by which UC-MSCs exert neuroprotective/neurorestorative effects was via a significant reduction in microgliosis in the peri-infarct cortex by high-dose UC-MSC injection, which modulates neuro-inflammation. Although cell replacement is considered a pivotal component in stem cell therapies including...
MSC therapies, accumulating studies have focused more on immunomodulation of the inflammatory microenvironment (56). Zhu et al. injected UC-MSCs intraperitoneally to a neonatal model of periventricular white matter damage and showed a decrease in reactive astrocytes and activated microglia in white matter (29). In post-ischemic tissue, M1 microglia are dominant and contribute to the inflammatory cascade and propagate cell death beyond the initial ischemic region (57, 58). With regard to macrophages, MSCs release factors that switch them from pro-inflammatory type 1 to an anti-inflammatory type 2 phenotype (59, 60) and produce TGF-β, which promotes the induction of Treg cells, ultimately leading to immune tolerance (61). Donega et al. demonstrated that transplanted MSCs modulate microglia to the immunosuppressive M2 type in neonatal ischemic brain injury (49). Our results also indicate that a reduction in microgliosis by intravenously injected UC-MSCs modulates the inflammatory cascade, which may contribute to the therapeutic efficacy rather than cell replacement. Further studies are needed to clarify mechanisms of stem cells actions, which may include electrophysiological and microstructural studies.

In conclusion, intravenous administration of UC-MSCs was safely performed in the small animal model of neonatal stroke mice, and the high dose (1 × 10^5) of UC-MSCs improved functional outcomes. We consider that one of the underlying mechanisms of the therapeutic effect was microglial immunomodulation.
ETHICS STATEMENT

All animal research was approved by the Experimental Animal Care and Use Committee of the National Cerebral and Cardiovascular Center and was done according to the NIH Guide for the Care and Use of Laboratory Animals.

AUTHOR CONTRIBUTIONS

ET performed the experiments (behavioral tests, etc.), analyzed data, prepared the figures, and wrote the manuscript. YO and TM performed the experiments (behavioral tests, etc.) and contributed to the analysis and interpretation of data. MT designed the study, performed the experiments (animal model, etc.), and critically reviewed the manuscript. YS, TH, TN, MS, and HS supervised the project and revised the manuscript critically for important intellectual content. All authors approved the manuscript.

ACKNOWLEDGMENTS

We would like to thank Satoshi Saito and Yumi Yamamoto for useful discussions and providing their expertise on experimental techniques. We thank Ritsuko Maki, Natsuki Hanada and Manami Sone for their excellent technical assistance.

FUNDING

The research was supported by the Joint Project Research of the Institute of Medical Science, the University of Tokyo (2017-1017), and the Japan Agency for Medical Research and Development (AMED) under Grant Number JP17gk0110022.

REFERENCES

1. Nelson KB, Lynch JK. Stroke in newborn infants. Lancet Neurol (2004) 3(3):150–8. doi:10.1016/s1474-4422(04)00679-9
2. Chabrier S, Husson B, Dinomais M, Landrieu P, Nguyen S. New insights (and new interrogations) in perinatal arterial ischemic stroke. Thromb Res (2011) 127(1):13–22. doi:10.1016/j.thromres.2010.10.003
3. Grunt S, Mazenauer L, Buerki SE, Bolshauser E, Mori AC, Datta AN, et al. Incidence and outcomes of symptomatic neonatal arterial ischemic stroke. Pediatrics (2015) 135(3):e1220–8. doi:10.1542/peds.2014-1520
4. Agrawal N, Johnston SC, Wu YW, Sidney S, Fullerton HJ. Imaging data reveal a higher pediatric stroke incidence than prior US estimates. Stroke (2009) 40(11):3415–21. doi:10.1161/STROKEAHA.109.564633
5. Lynch JK, Hirtz DG, DeWeber G, Nelson KB. Report of the national institute of neurological disorders and stroke workshop on perinatal and childhood stroke. Pediatrics (2002) 109(1):116–23. doi:10.1542/peds.109.1.116
6. Cowan F, Rutherford M, Groenendaal F, Eken P, Mercuri E, Bydder GM, et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet (2003) 361(9359):736–42. doi:10.1016/s0140-6736(03)12658-x
7. Cotten CM, Mutha AP, Goldberg RN, Grotegut CA, Smith PB, Goldstein RE, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr (2014) 164(5):973–9.e1. doi:10.1016/j.jpeds.2013.11.036
8. Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience (2014) 263:148–58. doi:10.1016/j.neuroscience.2014.01.018
9. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, et al. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. Dev Neurosci (2015) 37(2):95–104. doi:10.1159/000368396
10. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 9:12. doi:10.1186/1478-811X-9-12

FIGURE 7 | In vivo imaging of intravenously injected umbilical cord-derived MSCs (UC-MSCs). (A) Representative images of in vivo imaging taken at 3 h, 24 h, and 48 h and 4 days and 7 days after the intravenous injection of UC-MSCs. (B) Quantification of the total photon flux in the vehicle- and UC-MSC-treated groups. UC-MSCs were trapped in the lungs, and the intensity of photon flux decreased over time. We did not detect the signal in brain tissue (vehicle n = 1 and UC-MSC n = 7).
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284(5411):143–7. doi:10.1126/science.284.5411.143

12. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells (2004) 22(7):1330–7. doi:10.1634/stemcells.2004-0013

13. Liu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica (2006) 91(8):1017–26.

14. Kerst S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells (2006) 24(5):1294–301. doi:10.1634/stemcells.2005-0342

15. Amable PR, Teixeira MV, Cariai RB, Granjeiro JM, Borovjek R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Res Ther (2014) 5(2):53. doi:10.1186/s13287-014-0042

16. Mukai T, Mori Y, Shimazu T, Takahashi A, Tsuchida H, Yamaguchi S, et al. Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model. Neuroscience (2017) 355:175–87. doi:10.1016/j.neuroscience.2017.05.006

17. Kim ES, Ahn SY, Im GH, Sung DK, Park YR, Choi SH, et al. Umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res (2012) 72(3):277–84. doi:10.1038/pr.2012.71

18. van Velthoven CT, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, van Velthoven CT, et al. Human umbilical cord mesenchymal stem cell transplantation on glial cell and behavioral outcomes in a rodent model of periventricular white matter damage. Brain Res (2014) 1563:13–21. doi:10.1016/j.brainres.2013.03.030

19. Zhou X, Gu J, Gu Y, He M, Bi Y, Chen J, et al. Human umbilical cord-derived mesenchymal stem cells improve learning and memory function in hypoxic-ischemic brain-damaged rats via an IL-8-mediated secretion mechanism rather than differentiation pattern induction. Cell Physiol Biochem (2015) 35(6):2383–401. doi:10.1159/0003674040

20. Zhang DS, Bai XH, Chen DP, Mu DZ, Chen J. [Intracerebral transplantation of human umbilical cord-derived mesenchymal stem cells in neonatal rat model of hypoxic-ischemic brain damage: protective effect to injured brain]. Zhongguo Dang Dai Er Ke Za Zhi (2014) 16(9):927–32. doi:10.7499/j.1671-583X.2014.0913

21. Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, et al. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev (2015) 37(4):376–86. doi:10.1016/j.braindev.2014.06.010

22. de Paula S, Greggio S, Marinovic DR, Machado DC, DaCosta JC. The dose-response effect of acute intravenous transplantation of human umbilical cord blood cells on brain damage and spatial memory deficits in neonatal hypoxia-ischemia. Neuroscience (2012) 210:431–41. doi:10.1016/j.neuroscience.2012.03.009

23. Mukai T, Nagamura-Inoue T, Shimazu T, Mori Y, Takahashi A, Tsuda H, et al. Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model. Neuroscience (2017) 355:175–87. doi:10.1016/j.neuroscience.2017.05.006

24. Kim ES, Ahn SY, Im GH, Sung DK, Park YR, Choi SH, et al. Umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res (2012) 72(3):277–84. doi:10.1038/pr.2012.71

25. van Velthoven CT, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, van Velthoven CT, et al. Human umbilical cord mesenchymal stem cell transplantation on glial cell and behavioral outcomes in a rodent model of periventricular white matter damage. Brain Res (2014) 1563:13–21. doi:10.1016/j.brainres.2013.03.030

26. Zhou X, Gu J, Gu Y, He M, Bi Y, Chen J, et al. Human umbilical cord-derived mesenchymal stem cells improve learning and memory function in hypoxic-ischemic brain-damaged rats via an IL-8-mediated secretion mechanism rather than differentiation pattern induction. Cell Physiol Biochem (2015) 35(6):2383–401. doi:10.1159/0003674040

27. Zhang DS, Bai XH, Chen DP, Mu DZ, Chen J. [Intracerebral transplantation of human umbilical cord-derived mesenchymal stem cells in neonatal rat model of hypoxic-ischemic brain damage: protective effect to injured brain]. Zhongguo Dang Dai Er Ke Za Zhi (2014) 16(9):927–32. doi:10.7499/j.1671-583X.2014.0913

28. Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, et al. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev (2015) 37(4):376–86. doi:10.1016/j.braindev.2014.06.010

29. de Paula S, Greggio S, Marinovic DR, Machado DC, DaCosta JC. The dose-response effect of acute intravenous transplantation of human umbilical cord blood cells on brain damage and spatial memory deficits in neonatal hypoxia-ischemia. Neuroscience (2012) 210:431–41. doi:10.1016/j.neuroscience.2012.03.009

30. Mukai T, Nagamura-Inoue T, Shimazu T, Mori Y, Takahashi A, Tsuda H, et al. Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model. Neuroscience (2017) 355:175–87. doi:10.1016/j.neuroscience.2017.05.006

31. Kim ES, Ahn SY, Im GH, Sung DK, Park YR, Choi SH, et al. Umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res (2012) 72(3):277–84. doi:10.1038/pr.2012.71

32. van Velthoven CT, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, van Velthoven CT, et al. Human umbilical cord mesenchymal stem cell transplantation on glial cell and behavioral outcomes in a rodent model of periventricular white matter damage. Brain Res (2014) 1563:13–21. doi:10.1016/j.brainres.2013.03.030
46. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. *Exp Neurol* (2004) 189(1):58–65. doi:10.1016/j.expneurol.2004.01.011

47. Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Ibeda T. Progesterone and allopregnanolone exacerbate hypoxic-ischemic brain injury in immature rats. *Exp Neurol* (2012) 233(1):214–20. doi:10.1016/j.expneurol.2011.10.004

48. Donega V, van Velthoven CTJ, Nijboer CH, van Bel F, Kas MJH, Heijnen CJ, et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. *PLoS One* (2013) 8(1):e51253. doi:10.1371/journal.pone.0051253

49. Donega V, Nijboer CH, van Tilborg G, Dijkhuizen RM, Kavelaars A, Heijnen CJ. Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury. *Exp Neurol* (2014) 261:53–64. doi:10.1016/j.expneurol.2014.06.009

50. Cameron SH, Alwakeel AJ, Goddard L, Hobbs CE, Gowing EK, Barnett ER, et al. Delayed post-treatment with bone marrow-derived mesenchymal stem cells is neurorestorative of striatal medium-spiny projection neurons and improves motor function after neonatal rat hypoxia-ischemia. *Mol Cell Neurosci* (2015) 68:56–72. doi:10.1016/j.mcn.2015.03.019

51. Nagamura-Inoue T, Mukai T. Umbilical cord is a rich source of mesenchymal stromal cells for cell therapy. *Curr Stem Cell Res Ther* (2016) 11(8):634–42. doi:10.2174/1574888x10666151026115017

52. McDonald CA, Oehme D, Pham Y, Kelly K, Itescu S, Gibbon A, et al. Evaluation of the safety and tolerability of a high-dose intravenous infusion of allogeneic mesenchymal precursor cells. *Cytotherapy* (2015) 17(9):1178–87. doi:10.1016/j.jctv.2015.05.007

53. Gram M, Sveinssottir S, Cinthio M, Sveinssottir K, Hansson SR, Morgelin M, et al. Extracellular hemoglobin – mediator of inflammation and cell death in the choroid plexus following preterm intraventricular hemorrhage. *J Neuroinflammation* (2014) 11:200. doi:10.1186/s12974-014-0200-9

54. Liu WY, Wang ZB, Wang Y, Tong LC, Li Y, Wei X, et al. Increasing the permeability of the blood-brain barrier in three different models in vivo. *CNS Neurosci Ther* (2015) 21(7):568–74. doi:10.1111/cns.12405

55. Ahn SY, Chang YS, Sung DK, Sung SI, Ahn JY, Park WS. Pivotal role of brain-derived neurotrophic factor secreted by mesenchymal stem cells in severe intraventricular hemorrhage in newborn rats. *Cell Transplant* (2017) 26(1):145–56. doi:10.3727/096368916X692861

56. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. *Nat Immunol* (2014) 15(11):1009–16. doi:10.1038/ni.3002

57. Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. *J Neuroinflammation* (2014) 11:98. doi:10.1186/1742-2094-11-98

58. Berger R, Soder S. Neuroprotection in preterm infants. *Biomed Res Int* (2015) 2015:257139. doi:10.1155/2015/257139

59. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* (2009) 15(1):42–9. doi:10.1038/nm.1905

60. Abumaree MH, Al Jumah MA, Kailonis B, Jawdat D, Al Khalid A, Abomaray FM, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. *Stem Cell Rev* (2013) 9(5):620–41. doi:10.1007/s12015-013-9455-2

61. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. *Cell Stem Cell* (2012) 10(5):544–55. doi:10.1016/j.stem.2012.03.007

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Copyright © 2018 Tanaka, Ogawa, Mukai, Sato, Hamazaki, Nagamura-Inoue, Harada-Shiba, Shimata and Tsuji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.